Graceway selected I-many for its market-proven solutions and extensive experience in the health and life sciences industry. I-many met the company's criteria in the contract lifecycle management market space for low-risk products and unparalleled professional services that will enable them to effectively streamline their acquisition, maintain market presence, and optimize revenues.
"Graceway is a truly unique company -- a start-up with a proven management team and products that are projected to generate first year sales exceeding $350 million," said David Blumberg, I-many's executive vice president of fulfillment services. "By implementing the same I-many CLM solutions that enables top ten pharmaceutical companies to optimize revenues, Graceway is well on its way to garnering a significant share of a highly competitive marketplace."
About Graceway Pharmaceuticals, LLC
Graceway Pharmaceuticals, LLC, headquartered in Bristol, Tennessee, is a specialty pharmaceutical company focused on acquiring, in-licensing, and developing branded prescription pharmaceutical products. Current prescription products marketed by Graceway include Aldara(R), Atopiclair(TM), Benziq(TM), Maxair(TM) Autohaler(TM), Metrogel-Vaginal(R), Minitran(R), and Tambocor(R). Atopiclair is a license from Sinclair Pharma, plc.
"Graceway is a truly unique company -- a start-up with a proven management team and products that are projected to generate first year sales exceeding $350 million," said David Blumberg, I-many's executive vice president of fulfillment services. "By implementing the same I-many CLM solutions that enables top ten pharmaceutical companies to optimize revenues, Graceway is well on its way to garnering a significant share of a highly competitive marketplace."
About Graceway Pharmaceuticals, LLC
Graceway Pharmaceuticals, LLC, headquartered in Bristol, Tennessee, is a specialty pharmaceutical company focused on acquiring, in-licensing, and developing branded prescription pharmaceutical products. Current prescription products marketed by Graceway include Aldara(R), Atopiclair(TM), Benziq(TM), Maxair(TM) Autohaler(TM), Metrogel-Vaginal(R), Minitran(R), and Tambocor(R). Atopiclair is a license from Sinclair Pharma, plc.
About I-many(R)
I-many (NASDAQ:IMNY) is the leading provider of advanced Contract Lifecycle Management solutions for managing corporate commitments. Designed to extend beyond the traditional contract management capabilities, I-many ContractSphere(R) offers an end-to-end solution, from pre-contract processes and contract management to transaction compliance. Ultimately, this provides companies with the visibility and control needed to manage any type of commitment - from contracts and obligations to payments and collections. The result is increased revenue, minimized risk and dramatically reduced operating costs, which deliver improved profitability with hard return on investment. More than 280 customers across 21 industries worldwide have implemented and realized the value of I-many business solutions.
This news release contains forward-looking statements, and actual results may vary from those expressed or implied herein. Factors that could affect these results include: the risk of unforeseen technical or practical impediments to planned software development and other risk factors set forth from time to time in the Company's filings with the Securities and Exchange Commission.
SOURCE: I-many, Inc.
www.imany.com
I-many (NASDAQ:IMNY) is the leading provider of advanced Contract Lifecycle Management solutions for managing corporate commitments. Designed to extend beyond the traditional contract management capabilities, I-many ContractSphere(R) offers an end-to-end solution, from pre-contract processes and contract management to transaction compliance. Ultimately, this provides companies with the visibility and control needed to manage any type of commitment - from contracts and obligations to payments and collections. The result is increased revenue, minimized risk and dramatically reduced operating costs, which deliver improved profitability with hard return on investment. More than 280 customers across 21 industries worldwide have implemented and realized the value of I-many business solutions.
This news release contains forward-looking statements, and actual results may vary from those expressed or implied herein. Factors that could affect these results include: the risk of unforeseen technical or practical impediments to planned software development and other risk factors set forth from time to time in the Company's filings with the Securities and Exchange Commission.
SOURCE: I-many, Inc.
www.imany.com